Two physicians provided their thoughts on diagnosis of normal tension glaucoma, establishing true progression, and how to manage worsening disease in this patient population
Glaucoma specialists have now had the opportunity to come into the 21st century alongside some of the physicians in other medical specialties who have long used home monitoring devices to collect information on their patients’ conditions to better inform treatment.
This article recaps the 2023 Richard L. Lindstrom, MD, Lecture, titled “Glaucoma Surgery: Taking it to the Next Level,” given by Marlene Moster, MD, as well as the other presentations in the session, given by Cathleen McCabe, MD, Francis Mah, MD, and Daniel Chang, MD.
➤ FDA approves ophthalmic spray for mydriasis ➤ FDA accepts NDA for travoprost intraocular implant ➤ FDA accepts supplemental BLA for treatment for macular edema ➤ FDA 510(k) clearance granted to green pattern laser photocoagulator ➤ NDA submitted for pain and inflammation nanoemulsion ➤ Positive clinical results from IOP-monitoring contact lens ➤ Study provides real-world data comparing MIGS using IRIS Registry ➤ FDA approves IOL positioning system ➤ ASCRS news and events
MIGS procedures have become a mainstay in the treatment of mild to moderate glaucoma, but what pressures can physicians realistically expect with these? Three surgeons spoke about this, as well as how MIGS can fit into the overall glaucoma management process and what to do if MIGS procedures don’t achieve the desired IOP.
Glaucoma Editor Manjool Shah, MD, talks about what readers can expect in the Glaucoma section of the issue, as well as the value of ASCRS and the Annual Meeting. He also welcomes the newest members of the Glaucoma Editorial Board.
Two physicians shared their reasons for and experiences with combining MIGS procedures.
➤ FDA approves AI-based diabetic retinopathy screener ➤ FDA accepts NDA for Demodex treatment ➤ Phase 2b results for MGD therapy ➤ Phase 1/2 trial evaluates investigational TED treatment ➤ Phase 1 clinical trial to study synthetic cannabinoid derivative for glaucoma ➤ OCT company rebrands ➤ ASCRS news and events
➤ FDA approves new ocular surface anesthesia gel ➤ New drop approved to reduce IOP ➤ Newly available IOL incorporates technology that minimizes visual disturbances ➤ Interim data from Phase 1 trial for intravitreal implant to treat AMD ➤ Multiparty financing solution brought to ophthalmic practices ➤ Complimentary access to video journal ➤ ASCRS news and events
IOP elevation following intravitreal injections can be divided into short-term and long-term elevations. Short-term elevations are common, and some studies have estimated that they affect greater than 90% of patients.